Dbv Technologies S A SEC Filings

DBVT NASDAQ

Welcome to our dedicated page for Dbv Technologies S A SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading DBV Technologies’ SEC filings can feel like decoding a clinical protocol: pages of Phase 3 trial data, FDA queries, and cash-runway tables that bury the numbers investors need. If you have ever wondered where to locate “DBV Technologies insider trading Form 4 transactions” or how a single adverse-event footnote could change the company’s valuation, this page turns that challenge into clarity.

Stock Titan’s platform surfaces every document the moment it hits EDGAR and layers in AI-powered summaries that translate biotech jargon into plain English. Compare cash-burn trends in the latest “DBV Technologies quarterly earnings report 10-Q filing,” follow “DBV Technologies Form 4 insider transactions real-time,” and get “DBV Technologies SEC filings explained simply” without opening a spreadsheet. Our analysis ties each filing type to issues unique to a development-stage allergen patch maker: the viability of Viaskin’s pivotal trials, milestone payments from partners, and regulatory milestones outlined in every “DBV Technologies 8-K material events explained.”

Use cases are practical. Track management confidence by monitoring “DBV Technologies executive stock transactions Form 4,” review cash-flow assumptions with our “DBV Technologies earnings report filing analysis,” and see dilution risk before secondary offerings appear. Need the big picture? Our AI condenses the 200-page “DBV Technologies annual report 10-K simplified,” highlights FDA correspondence, and even flags the “DBV Technologies proxy statement executive compensation” section so you can benchmark pay against pipeline progress. Whether you’re assessing immunotherapy trial endpoints or planning to trade around catalyst dates, “understanding DBV Technologies SEC documents with AI” starts here—and happens in seconds.

06/25/2025 04:32 PM

Filing

[8-K] DBV Technologies S.A. Reports Material Event

Rhea-AI Summary

DBV Technologies announced a significant milestone in its clinical research program with the first subject screening in the COMFORT Toddlers Supplemental Safety Study, focusing on peanut-allergic children aged 1-3 years old. This development marks an important step in the company's research into peanut allergy treatments.

The company, which trades on Nasdaq under symbol DBVT through American Depositary Shares (each representing five ordinary shares), filed this 8-K to report the initiation of this clinical study. The announcement was made via press release on June 25, 2025.

Key filing details:

The study specifically targets toddlers between 1-3 years old with peanut allergies
The filing includes two exhibits: the press release (99.1) and Cover Page Interactive Data File
The document was signed by CFO Virginie Boucinha

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.6%

[S-8] DBV Technologies S.A. Employee Benefit Plan Registration

Rhea-AI Summary

DBV Technologies has filed a Form S-8 registration statement to register securities related to its 2025 Stock Option Plan and 2025 Free Share Plan. The company, headquartered in Châtillon, France, is classified as a non-accelerated filer and smaller reporting company.

Key aspects of the filing include:

Registration incorporates previous S-8 filings from October 2014, November 2023, and July 2024
Includes the company's Annual Report for FY2024 and Q1 2025 Quarterly Report
Maintains liability insurance for directors and officers with contractual indemnification provisions
French law prohibits limiting director liability but allows insurance against civil liabilities

The registration is signed by CEO Daniel Tassé and includes authorization from the full board of directors. Michele Robertson serves as the authorized U.S. representative in her capacity as Chief Legal Officer. The filing demonstrates DBV Technologies' commitment to employee equity compensation while maintaining compliance with both U.S. and French regulatory requirements.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Dbv Technologies S A (DBVT)?

The current stock price of Dbv Technologies S A (DBVT) is $8.88 as of June 28, 2025.

What is the market cap of Dbv Technologies S A (DBVT)?

The market cap of Dbv Technologies S A (DBVT) is approximately 234.1M.

What is the core focus of DBV Technologies SA?

DBV Technologies SA focuses on developing innovative immunotherapy treatments using its proprietary EPIT technology, primarily targeting food allergies such as peanut allergy.

How does the Viaskin technology work?

The Viaskin patch delivers allergens to the skin, targeting Langerhans cells to promote a localized immune response while minimizing systemic exposure, thus enhancing patient safety.

What differentiates DBV Technologies from other allergy treatment companies?

The company differentiates itself through its unique epicutaneous immunotherapy approach, a non-invasive treatment strategy that emphasizes both efficacy and safety for managing food allergies.

What is epicutaneous immunotherapy (EPIT)?

EPIT is a therapeutic approach that involves administering allergens via a skin patch to stimulate the immune system in a controlled manner, reducing the risk of severe allergic reactions.

How does DBV Technologies generate value during its clinical development stages?

The company’s value is derived from reaching clinical milestones, strategic partnerships, and potential licensing opportunities as it advances its clinical-stage products toward market approval.

Can the Viaskin technology be applied to allergies other than peanut?

While the primary focus is on peanut allergy, DBV Technologies’ platform has the potential to be extended to other food allergies, leveraging the same core principles of epicutaneous immunotherapy.

What role do Langerhans cells play in DBV Technologies' treatment approach?

Langerhans cells are key antigen-presenting cells in the skin that capture allergens delivered by the Viaskin patch, initiating a local immune response that aids in reducing allergic sensitivity.

How does DBV Technologies contribute to addressing the unmet medical need in food allergy treatments?

By developing a novel, safe, and effective immunotherapy platform, the company addresses a significant public health concern, offering an alternative for patients who are at risk of severe allergic reactions.